AEON Biopharma, Inc.
AEON NYSE Pharmaceutical Preparations Financials FY2021–FY2025
Last close · Oct 23, 2026
$0.24
2.7%
Revenue
Total sales reported in the income statement.
—
vs prior year
Operating margin
Operating income as a share of revenue.
—
Net income
Profit after all expenses, interest and tax.
−$39.2M
Free cash flow
Cash from operations minus capital spending.
−$17.3M
Return on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
—
Market cap
Last close times the latest diluted share count, so it is approximate.
$12.1M
Oct 23 close
P/E
Last close divided by diluted earnings per share over the last four quarters.
—
On −$5.94 EPS (TTM)
What AEON Biopharma, Inc. does
No business description yet.
- Legal name
- AEON Biopharma, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 30, 2026
- Accession · CIK
- 0001837607-26-000019
0001837607
Revenue and margins
AEON Biopharma, Inc. had — of revenue in fiscal 2025.
FY21
Revenue —
FY22
Revenue —
FY24
Revenue —
FY25
Revenue —
FY21
Gross —
Operating —
Net —
FCF —
FY22
Gross —
Operating —
Net —
FCF —
FY24
Gross —
Operating —
Net —
FCF —
FY25
Gross —
Operating —
Net —
FCF —
Gross
Operating
Net
FCF
Net income and earnings per share
Loss periods are shown in red.
FY21
Net income $8.2M
FY22
Net income −$52.6M
FY24
Net income —
FY25
Net income −$39.2M
Q3 '22
Net income −$10.4M
Q4 '22
Net income −$34.6M
Q1 '24
Net income −$17.6M
Q2 '24
Net income −$15.4M
Q3 '24
Net income −$27.7M
Q4 '24
Net income −$6.2M
Q1 '25
Net income $9.1M
Q2 '25
Net income −$6.6M
Q3 '25
Net income −$4.5M
Q4 '25
Net income −$37.1M
Q1 '26
Net income −$11.8M
Q2 '26
Net income −$1.2M
FY21
Diluted EPS —
FY22
Diluted EPS −$0.38
FY24
Diluted EPS —
FY25
Diluted EPS −$3.95
Q3 '22
Diluted EPS −$0.08
Q4 '22
Diluted EPS —
Q1 '24
Diluted EPS −$0.13
Q2 '24
Diluted EPS −$0.11
Q3 '24
Diluted EPS —
Q4 '24
Diluted EPS −$11.24
Q1 '25
Diluted EPS $2.28
Q2 '25
Diluted EPS −$0.60
Q3 '25
Diluted EPS −$0.39
Q4 '25
Diluted EPS −$5.24
Q1 '26
Diluted EPS −$0.29
Q2 '26
Diluted EPS −$0.02
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
FY21
Return on capital —
Return on equity —
Return on assets 3.0%
FY22
Return on capital —
Return on equity —
Return on assets −36.5%
FY24
Return on capital —
Return on equity —
Return on assets —
FY25
Return on capital —
Return on equity —
Return on assets −901.4%
Return on capital
Return on equity
Return on assets
Cash flow
Free cash flow was −$17.3M in fiscal 2025, — of revenue. Cash from operations minus capital spending.
FY21
Free cash flow —
FY22
Free cash flow −$35.9M
FY24
Free cash flow —
FY25
Free cash flow −$17.3M
Q3 '22
Free cash flow —
Q4 '22
Free cash flow −$8.5M
Q1 '24
Free cash flow —
Q2 '24
Free cash flow —
Q3 '24
Free cash flow —
Q4 '24
Free cash flow —
Q1 '25
Free cash flow −$7.9M
Q2 '25
Free cash flow −$2.1M
Q3 '25
Free cash flow −$2.6M
Q4 '25
Free cash flow −$4.7M
Q1 '26
Free cash flow —
Q2 '26
Free cash flow —
FY21
Cash from operations −$1.5M
Capital spending —
FY22
Cash from operations −$35.6M
Capital spending $0.3M
FY24
Cash from operations —
Capital spending —
FY25
Cash from operations −$17.3M
Capital spending $0.0M
Cash from operations
Capital spending
Q3 '22
Cash from operations −$26.6M
Capital spending —
Q4 '22
Cash from operations −$8.5M
Capital spending $0.0M
Q1 '24
Cash from operations −$11.1M
Capital spending —
Q2 '24
Cash from operations −$10.1M
Capital spending —
Q3 '24
Cash from operations —
Capital spending —
Q4 '24
Cash from operations −$8.6M
Capital spending —
Q1 '25
Cash from operations −$7.9M
Capital spending $0.0M
Q2 '25
Cash from operations −$2.1M
Capital spending $0.0M
Q3 '25
Cash from operations −$2.6M
Capital spending $0.0M
Q4 '25
Cash from operations −$4.7M
Capital spending $0.0M
Q1 '26
Cash from operations −$2.6M
Capital spending —
Q2 '26
Cash from operations −$3.7M
Capital spending —
Cash from operations
Capital spending
Dividends, buybacks and share count
AEON Biopharma, Inc. returned — to shareholders in fiscal 2025. The diluted share count rose 0.0%.
FY21
Dividends —
Buybacks —
FY22
Dividends —
Buybacks —
FY24
Dividends —
Buybacks —
FY25
Dividends —
Buybacks —
Dividends
Buybacks
FY21
Diluted shares —
FY22
Diluted shares 0.14B
FY24
Diluted shares —
FY25
Diluted shares 0.01B
Balance sheet
Cash, debt and the ratios that show how comfortably AEON Biopharma, Inc. can carry it.
FY21
Cash $0.5M
Debt —
FY22
Cash $9.7M
Debt —
FY24
Cash $0.0M
Debt —
FY25
Cash $3.0M
Debt —
Cash
Debt
| Fiscal year end | FY21 | FY22 | FY24 | FY25 |
|---|---|---|---|---|
| Cash and short-term investments | $0.5M | $9.7M | $0.0M | $3.0M |
| Current ratio | 1.0x | 0.1x | 0.1x | 0.5x |
| Quick ratio | 1.0x | 0.1x | 0.1x | 0.5x |
| Total assets | $277M | $10.8M | $3.1M | $5.6M |
| Total liabilities | $17.9M | $143M | $31.7M | $60.6M |
| Shareholders' equity | −$16.9M | −$288M | −$28.6M | −$55.0M |
| Net debt (− = net cash) | — | — | — | — |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY21 | FY22 | FY25 |
|---|---|---|---|
| Net income is positive | ✓ | ✕ | ✕ |
| Cash from operations is positive | ✕ | ✕ | ✕ |
| Return on assets rose | — | ✕ | — |
| Cash from operations exceeds net income | ✕ | ✓ | ✓ |
| Debt fell relative to assets | — | — | — |
| Current ratio rose | — | ✕ | ✓ |
| Share count didn't rise | — | — | — |
| Gross margin rose | — | — | — |
| Revenue rose relative to assets | — | — | — |
| F-score | — / 3 | — / 5 | — / 4 |
| Accruals ratio | 3.5% | −11.8% | −503.7% |
| Altman Z'' | −1.24 | −220.20 | −296.61 |
4 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY21 | FY22 | FY24 | FY25 |
|---|---|---|---|---|
| Income statement | ||||
| Research and development | — | $34.8M | — | $4.1M |
| Operating income | −$1.9M | −$48.4M | — | −$12.8M |
| Pretax income | $8.2M | −$52.6M | — | −$39.2M |
| Income tax | — | $0.0M | — | $0.0M |
| Net income | $8.2M | −$52.6M | — | −$39.2M |
| Net income to common | — | −$52.6M | — | −$39.2M |
| Diluted EPS | — | −$0.38 | — | −$3.95 |
| Diluted shares | — | 0.14B | — | 0.01B |
| Cash flow | ||||
| Cash from operations | −$1.5M | −$35.6M | — | −$17.3M |
| Capital expenditure | — | $0.3M | — | $0.0M |
| Free cash flow | — | −$35.9M | — | −$17.3M |
| Depreciation and amortization | — | $0.1M | — | $0.1M |
| Stock-based compensation | — | $5.9M | — | $5.3M |
| Balance sheet | ||||
| Cash and short-term investments | $0.5M | $9.7M | $0.0M | $3.0M |
| Current assets | $0.8M | $9.8M | $1.6M | $3.4M |
| Current liabilities | $0.8M | $82.6M | $14.1M | $6.9M |
| Property and equipment, net | — | $0.4M | $0.2M | $0.2M |
| Total assets | $277M | $10.8M | $3.1M | $5.6M |
| Total liabilities | $17.9M | $143M | $31.7M | $60.6M |
| Preferred stock | $0.0M | — | — | — |
| Shareholders' equity | −$16.9M | −$288M | −$28.6M | −$55.0M |
| Returns | ||||
| Return on capital employed | −0.7% | 67.5% | — | 957.6% |
| Return on assets | 3.0% | −36.5% | — | −901.4% |
| Growth | ||||
| Net income growth | — | −740.9% | — | — |
| Financial health | ||||
| Current ratio | 1.0x | 0.1x | 0.1x | 0.5x |
| Quick ratio | 1.0x | 0.1x | 0.1x | 0.5x |
| Quality scores | ||||
| Altman Z'' | −1.2 | −220.2 | — | −296.6 |
| Accruals ratio | 3.5% | −11.8% | — | −503.7% |
Source: SEC EDGAR XBRL filings (CIK 0001837607). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.